Dr. Reddy’s and Novartis India are ending their four-year commercial partnership, signed on February 11, 2022. Dr. Reddy’s will continue commercialisation of the affected brands until September 30, 2026. The termination allows Novartis India to regain exclusive market access and directly manage its portfolio. Both parties agreed amicably on the dissolution terms, with no further details disclosed publicly.
The development follows private equity firm ChrysCapital acquiring a 70.68% controlling stake in Novartis India. This marks ChrysCapital’s first majority-controlled investment in India’s pharmaceutical sector and underscores its confidence in the branded medicines market’s growth. Novartis India’s portfolio covers pain management, calcium supplementation, gynaecology, neurosciences, and transplant immunology, with brands such as Voveran, Calcium Sandoz, and Tegrital.
